Table 1.
Baseline characteristics of patients with rectal cancer who underwent robotic proctectomy between April 2009 and April 2016 (N=276).*
| Characteristic | |
|---|---|
|
| |
| Mean age (SD), years | 54 (12) |
|
| |
| Sex | |
| Male | 168 (60.9) |
| Female | 108 (39.1) |
|
| |
| Ethnicity | |
| Caucasian | 236 (85.5) |
| African American | 15 (5.4) |
| Asian | 20 (7.2) |
| Other | 5 (1.8) |
|
| |
| Median BMI (IQR) | 27.0 (7.2) |
|
| |
| ASA score | |
| I | 0 |
| II | 63 (22.8) |
| III | 210 (76.1) |
| IV | 3 (1.1) |
|
| |
| Previous abdominal surgery | 63 (22.8) |
|
| |
| Pre-treatment AJCC staging | |
| I | 42 (15.2) |
| II | 34 (12.3) |
| III | 176 (63.8) |
| IV | 24 (8.7) |
|
| |
| Clinical T stage (cT) | |
| T0 / Tis | 9 (3.3) |
| T1 | 13 (5.7) |
| T2 | 43 (15.6) |
| T3 | 185 (67.0) |
| T4 | 26 (9.5) |
|
| |
| Clinical N stage (cN) | |
| N0 | 86 (31.2) |
| N1 | 137 (49.6) |
| N2 | 53 (19.2) |
|
| |
| Clinical M stage (cM) | |
| M0 | 252 (91.3) |
| M1 | 24 (8.7) |
|
| |
| Neo-adjuvant treatment | |
| Long course chemo-radiotherapy | 171 (61.9) |
| Short course radiotherapy | 1 (0.4) |
| Induction chemotherapy, followed by radiotherapy | 14 (5.1) |
| Chemotherapy only | 20 (7.2) |
| Did not receive neo-adjuvant treatment | 70 (25.4) |
|
| |
| Adjuvant treatment | |
| FOLFOX / CAPOX | 125 (45.3) |
| Fluorouracil / Capecitabine only | 76 (27.5) |
| FOLFOX + Bevacizumab | 12 (4.3) |
| FOLFIRI + Bevacizumab | 8 (2.9) |
| Other | 5 (1.8) |
| Did not receive chemotherapy | 50 (18.9) |
|
| |
| Median time to adjuvant treatment (IQR), days | 42 (21) |
*
Data are number of patients (%) unless otherwise indicated.
Abbreviations: SD, Standard Deviation; BMI, body mass index; IQR, Inter-quartile range; ASA, American Society of Anesthesiologists; AJCC, American Joint Committee on Cancer; FOLFOX, Folinic acid + Fluorouracil + Oxaliplatin; CAPOX: Capecitabine + Oxaliplatin; FOLFIRI: Folinic acid + Fluorouracil + Irinotecan.